{"id":2965,"date":"2026-09-08T06:00:00","date_gmt":"2026-09-08T10:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2965"},"modified":"2026-09-08T20:40:29","modified_gmt":"2026-09-09T00:40:29","slug":"mosliciguat-lowers-pulmonary-vascular-resistance-in-ph-ild","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2965","title":{"rendered":"Mosliciguat Lowers Pulmonary Vascular Resistance in PH ILD"},"content":{"rendered":"

Evidence<\/strong> Source gap catch-up · Published<\/strong> September 8, 2026 · Discovery<\/strong> September 8, 2026 · Importance<\/strong> 5\/5 · Direction<\/strong> Positive<\/p>\n

\"Mosliciguat<\/p>\n

Summary<\/h4>\n

Roivant and its Pulmovant subsidiary reported a large, internally consistent randomized Phase II signal for once-daily inhaled mosliciguat in pulmonary hypertension associated with interstitial lung disease. At Week 16, pulmonary vascular resistance fell 56.3% versus placebo, six-minute walk distance improved by 35.2 meters and NT-proBNP fell 53.2%. All three comparisons were statistically significant. The result materially strengthens the molecule-specific thesis and supports the ongoing Phase III PHrontier trial, but it does not establish morbidity, mortality, durability, comparative efficacy or a complete benefit-risk profile.<\/p>\n

What Happened<\/h4>\n

PHocus randomized 135 adults across 87 sites in 20 countries in a double-blind, placebo-controlled design. At Week 16, pulmonary vascular resistance changed by minus 51.3% with mosliciguat and plus 6.6% with placebo, for a placebo-adjusted reduction of 56.3% (p<0.0001). Placebo-adjusted six-minute walk distance improved 35.2 meters (plus 20.3 versus minus 14.9; p=0.0027). NT-proBNP, a marker of cardiac strain, fell by 357.7 pg\/mL or 53.2% versus placebo (p=0.0002).<\/p>\n

Prespecified exploratory Week 24 analyses showed a 52.7-meter placebo-adjusted walk-distance difference and a 487.1 pg\/mL, or 75.9%, NT-proBNP reduction; both nominal p values were below 0.0001. Cough occurred in 12.1% on mosliciguat and 18.2% on placebo. The company characterized overall tolerability as favorable but did not disclose full adverse-event, serious-event, discontinuation or systemic-hemodynamic tables in the release. PHrontier has begun and is designed to enroll about 375 patients.<\/p>\n

Deep Analysis<\/h4>\n

A coherent pharmacologic effect:<\/strong> Concordant changes in pulmonary hemodynamics, exercise capacity and cardiac strain reduce the chance that the signal reflects one noisy endpoint. The inhaled route and nitric-oxide-independent activation of soluble guanylate cyclase provide a plausible mechanism for pulmonary-selective vasodilation in oxidatively stressed lung vasculature. PVR and NT-proBNP are intermediate measures, six-minute walk distance is effort-sensitive and the release provides no clinical-worsening or survival analysis.<\/p>\n

A favorable short trial may overstate real-world differentiation:<\/strong> The placebo group lost walking distance and the reported efficacy comes from a selected trial population under protocolized care. PH-ILD is heterogeneous by fibrosis cause, severity, background therapy and ventilation-perfusion physiology. Without subgroup estimates, confidence intervals, oxygenation data and a complete safety table, it is not yet clear whether the average response generalizes or whether vasodilation worsens gas exchange in a susceptible subset. No active comparison with inhaled treprostinil was performed.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts include randomization, 135 participants, three significant Week 16 endpoints, sustained exploratory Week 24 separation and Phase III initiation. Company claims that the PVR reduction is the largest reported in a randomized controlled pulmonary-hypertension trial are not independently established here. Missing facts include full baseline balance, confidence intervals, multiplicity details, oxygenation, hospitalization, clinical worsening, mortality, drug discontinuations, serious events and background-treatment interactions.<\/p>\n

Company and Product Background<\/h4>\n

Roivant develops medicines through focused subsidiaries. Pulmovant is advancing mosliciguat for Group 3 pulmonary hypertension caused by interstitial lung disease, a setting in which fibrotic parenchymal injury and pulmonary vascular remodeling raise right-heart load, impair exercise capacity and confer high mortality. Inhaled treprostinil is the principal approved U.S. therapy; phosphodiesterase-5 inhibitors are also used off label. Cross-trial efficacy comparisons are unreliable because populations, endpoint timing and background care differ.<\/p>\n

Mosliciguat is an inhaled activator of soluble guanylate cyclase, the enzyme that produces cyclic GMP downstream of nitric oxide. Unlike sGC stimulators, activators are designed to engage oxidized or heme-free enzyme independently of nitric oxide. Increased cyclic GMP relaxes vascular smooth muscle and may influence remodeling, inflammation and fibrosis, although the latter effects are not demonstrated clinically by PHocus. Inhalation is intended to concentrate exposure in the lung and limit systemic hypotension.<\/p>\n

InSilens Take<\/h4>\n

Mosliciguat produced one of the strongest Phase II pulmonary-vascular packages disclosed this year: the effect spans hemodynamics, function and cardiac strain, and it strengthened through Week 24. That supports a positive directional score for this specific study. It does not justify claims of survival benefit, class leadership or commercial readiness. The decisive evidence is now Phase III replication with clinically consequential endpoints, complete safety and oxygenation data, and performance across PH-ILD phenotypes and background therapy.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n5 \/ 5 — a randomized global study generated a large and coherent efficacy package in a severe disease and moved directly into Phase III<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nPositive — the prespecified primary and secondary endpoints favored mosliciguat with strong nominal or controlled significance<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — design, sample size, endpoint changes and p values disclosed in the primary corporate release and linked registry<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate-high — robust for short-term physiologic and functional benefit, but clinical outcomes, detailed safety and external replication remain missing<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Roivant and its Pulmovant subsidiary reported a large, internally consistent randomized Phase II signal for once-daily inhaled mosliciguat in pulmonary hypertension associated with interstitial lung disease. At Week 16, pulmonary vascular resistance fell 56.3%…<\/p>\n","protected":false},"author":1,"featured_media":2970,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[626,627,625,624],"class_list":["post-2965","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-mosliciguat","tag-pulmonary-hypertension","tag-pulmovant","tag-roivant-sciences"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2965"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2965\/revisions"}],"predecessor-version":[{"id":2997,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2965\/revisions\/2997"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2970"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}